Tag: AI Drug Discovery
Nutshell can begin testing its molecular glue on US patients
The Shanghai biotech won clearance for NTS231, a compound aimed at a protein that helps tumors survive treatment.
XtalPi’s first home-grown molecule heads for US trials
The AI drug discovery firm filed an IND for a pain candidate built to act inside the gut and stay…
Roche steers CHF 2B of savings into self-driving drug labs
Roche told investors it wants research that needs fewer hands on deck, an ambition the company frames as AI independence.
BigHat’s robot lab reaches the clinic on a $75M round
BigHat's Milliner platform pairs frontier models with automated lab work, and its first antibody-drug conjugate is now in patients.
Absci lines up a 150-patient test of its generative antibody
Absci's STORYLINE trial would test a generative-AI-designed antibody in about 150 endometriosis patients starting mid-2027.
Basecamp Research targets DNA editing from inside the body
The London biotech's Series C values it at $800 million and funds EDEN models aimed at rewriting a patient's cells…
Enveda lands $311M to move three medicines into late-stage trials
Enveda closed a $311 million Series E led by Catalio to push three clinical-stage medicines deeper into development.
Boehringer bets up to $1B on RNA splicing targets from Envisagenics
The New York company will mine alternative splicing for tumor-specific targets that drug makers can turn into therapies.